Vergoeding 2018-2022 voor ATC-subgroep J05A : Direct werkende antivirale middelen
- Raming voor de totale Zvw-populatie
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| J05AB Nucleosiden en nucleotiden (excl. reverse-transcr-remmers) | 4.390.500 | 4.572.700 | 5.912.800 | 4.683.500 | 4.679.400 |
| J05AD Fosfonzuurderivaten | 34.620 | 14.629 | 1.292 | 5.850 | 9.480 |
| J05AE Proteaseremmers | 11.719.100 | 7.098.600 | 3.408.600 | 1.941.000 | 1.437.800 |
| J05AF Nucleoside en nucleotide reverse-transcriptaseremmers | 7.970.200 | 4.726.600 | 4.977.100 | 4.502.800 | 4.601.500 |
| J05AG Niet-nucleoside reverse-transcriptaseremmers | 4.349.700 | 3.089.000 | 2.920.300 | 2.745.900 | 3.409.200 |
| J05AJ Integraseremmers | 19.952.500 | 20.985.000 | 19.297.900 | 17.341.700 | 20.253.700 |
| J05AP Antivirale middelen voor behandeling van hcv-infecties | 36.979.800 | 18.584.200 | 11.431.900 | 10.664.400 | 9.442.700 |
| J05AR Antivirale middelen voor hivinfectie combinatiepreparaten | 137.402.300 | 142.137.500 | 142.975.500 | 137.652.100 | 145.363.600 |
| J05AX Overige antivirale middelen | 766.600 | 1.122.700 | 1.761.800 | 2.448.000 | 3.396.500 |
| Totaal | 223.565.320 | 202.330.929 | 192.687.192 | 181.985.250 | 192.593.880 |